Healthy Payout Possible for Carlyle From Nature’s BountyBy
Nutritional supplements are having a healthy effect on Carlyle. The buyout firm may be ready to part with Nature’s Bounty. At the $6 billion price tag reported by Bloomberg, it would deliver a substantial return for what was a pivotal deal in 2010.
At the time, it was Carlyle’s biggest leveraged buyout in years. The firm, led by David Rubenstein, had been presciently cautious starting in 2007, and NBTY, as the vitamin seller was known then, was its first sizable acquisition since the financial crisis. It also was not obvious how to wring a better return out of the company, given its financial performance. Carlyle said only that it wanted to “drive continued growth.”…
Leave a Reply
You must be logged in to post a comment.